Related Experiment Video
Updated: Jul 10, 2026
Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts
Published on: February 11, 2014
Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term
Sisto Perdonà1, Riccardo Autorino, Rocco Damiano
1Comprehensive Urology Unit, National Tumor Institute, G. Pascale Foundation, Naples, Italy.
Background:
The authors evaluated their long-term experience with combined-modality, conservative treatment in patients with muscle-invasive bladder cancer.
Methods:
In total, 121 patients with T2, T3, or T4 bladder cancer (mean age, 63 years; ratio of men to women, 3:1) underwent induction by transurethral resection (TUR) of the tumor and received 2 cycles of neoadjuvant chemotherapy followed by radiotherapy (RT) (n = 43 patients) or radiochemotherapy (RCT) (n = 78 patients). Six weeks after RT or RCT, responses were evaluated by restaging TUR. Patients who achieved a complete response (CR) were observed at regular intervals. In patients who had persistent or recurrent invasive tumor, further treatment was recommended.
Results:
Local response evaluation by restaging TUR was possible in 119 patients, and 102 of those patients (85.7%) achieved a CR. After a median follow-up of 66 months (range, 6-182 months), no local or distant disease recurrences were observed in 67 of 102 complete responders (65.7%), 17 of 102 complete responders (16.7%) experienced superficial local disease recurrence, and 18 of 102 complete responders (17.6%) had a muscle-invasive relapse. The 5-year tumor-specific, overall, and bladder-intact survival rates were 73.5%, 67.7%, and 51.2%, respectively. Treatment modality, tumor classification, and resection status after initial TUR had an impact on survival rates (P = .04, P = .02, and P = .02, respectively).
Conclusions:
The current results indicated that conservative combined treatment is a reasonable alternative to radical cystectomy in selected patients with muscle-invasive bladder cancer.
